
No Improvement in Treatment Success with Teriparatide Use for Hip and Pelvic Bone Fractures

No Improvement in Treatment Success with Teriparatide Use for Hip and Pelvic Bone Fractures
Effects of Teriparatide on Treatment Outcomes in Osteoporotic Hip and Pelvic Bone Fractures: Meta-analysis and Systematic Review of Randomized Controlled Trials.
Hip Pelvis. 2020 Dec; 32(4): 182–191.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
A total of 5 randomized controlled trials containing a total of 386 patients were included in this meta-analysis comparing teriparatide (n=181) and placebo (n=205) for the treatment of osteoporotic hip and pelvic bone fractures. The primary outcome of interest was the pooled incidence of treatment failure. Mean follow up of the included studies ranged from 3 to 19.5 months. Results of the meta-ana...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Learn about our AI Driven
High Impact Search Feature

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.